https://www.businesswire.com/news/home/20260323044518/en/Consortium-Led-by-Axelspace-Selected-for-Japans-Space-Strategy-Fund-Project-Technology-to-Enhance-Capability-of-Next-Generation-Earth-Observation-Satellites 2026-03-29T23:35:00.000Z weekly 0.5 Business Wire en PressRelease 2026-03-29T23:35:00.000Z Consortium Led by Axelspace Selected for Japan’s Space Strategy Fund Project “Technology to Enhance Capability of Next Generation Earth Observation Satellites” https://mms.businesswire.com/media/20260323044518/en/2754434/21/CO2_EN.jpg https://www.businesswire.com/news/home/20260323261716/ja 2026-03-29T23:35:00.000Z weekly 0.5 Business Wire ja PressRelease 2026-03-29T23:35:00.000Z アクセルスペース、連携機関3社とともに宇宙戦略基金「次世代地球観測衛星に向けた観測機能高度化技術」に採択 https://mms.businesswire.com/media/20260323261716/ja/2754434/21/CO2_EN.jpg https://www.businesswire.com/news/home/20260328854426/pt 2026-03-29T19:15:00.000Z weekly 0.5 Business Wire pt PressRelease 2026-03-29T19:15:00.000Z A Debevoise obtém confirmação, pelo Tribunal de Apelações do Segundo Circuito, da rejeição de ação de US$ 16 bilhões contra a YPF S.A. https://www.businesswire.com/news/home/20260328644517/es 2026-03-29T19:14:00.000Z weekly 0.5 Business Wire es PressRelease 2026-03-29T19:14:00.000Z Debevoise obtiene la confirmación del Segundo Circuito de la desestimación de una demanda de 16 000 millones de dólares contra YPF S.A. https://www.businesswire.com/news/home/20260328692002/fr 2026-03-29T17:51:00.000Z weekly 0.5 Business Wire fr PressRelease 2026-03-29T17:51:00.000Z Incyte annonce de nouvelles données positives de dernière minute portant sur 54 semaines concernant le povorcitinib dans le traitement de l’hidradénite suppurée lors du congrès annuel 2026 de l’Académie américaine de dermatologie (AAD) INCY https://mms.businesswire.com/media/20260328692002/fr/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260328736289/nl 2026-03-29T17:10:00.000Z weekly 0.5 Business Wire nl PressRelease 2026-03-29T17:10:00.000Z Samenvatting: Incyte maakt nieuwe positieve, recent bekendgemaakte gegevens over een periode van 54 weken bekend voor povorcitinib bij hidradenitis suppurativa tijdens de jaarlijkse bijeenkomst van de American Academy of Dermatology (AAD) in 2026 INCY https://mms.businesswire.com/media/20260328736289/nl/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260328429632/it 2026-03-29T17:10:00.000Z weekly 0.5 Business Wire it PressRelease 2026-03-29T17:10:00.000Z Riassunto: Incyte annuncia gli ultimi nuovi dati positivi ottenuti in 54 settimane su povorcitinib nell'idrosadenite suppurativa al Meeting annuale 2026 della American Academy of Dermatology (AAD) INCY https://mms.businesswire.com/media/20260328429632/it/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260328233200/de 2026-03-29T17:10:00.000Z weekly 0.5 Business Wire de PressRelease 2026-03-29T17:10:00.000Z Incyte präsentiert neue positive 54-Wochen-Daten zu Povorcitinib bei Hidradenitis suppurativa auf der Jahrestagung 2026 der American Academy of Dermatology (AAD) INCY https://mms.businesswire.com/media/20260328233200/de/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260328087840/es 2026-03-29T17:10:00.000Z weekly 0.5 Business Wire es PressRelease 2026-03-29T17:10:00.000Z Resumen: Incyte anuncia nuevos datos positivos de última hora a las 54 semanas sobre el povorcitinib para la hidradenitis supurativa en el 2026 American Academy of Dermatology (AAD) Annual Meeting INCY https://mms.businesswire.com/media/20260328087840/es/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260329952162/en/Positive-Data-from-Phase-2-CADENCE-Trial-Provides-Definitive-Proof-of-Concept-for-WINREVAIR-sotatercept-csrk-in-Adults-With-the-Syndrome-of-Combined-Post--and-Precapillary-Pulmonary-Hypertension-and-Heart-Failure-With-Preserved-Ejection-Fraction 2026-03-29T15:45:00.000Z weekly 0.5 Business Wire en PressRelease 2026-03-29T15:45:00.000Z Positive Data from Phase 2 CADENCE Trial Provides Definitive Proof-of-Concept for WINREVAIR™ (sotatercept-csrk) in Adults With the Syndrome of Combined Post- and Precapillary Pulmonary Hypertension and Heart Failure With Preserved Ejection Fraction MRK https://mms.businesswire.com/media/20260329952162/en/1106824/21/Merck_Logo_Horizontal_Teal-Grey_RGB.jpg https://www.businesswire.com/news/home/20260329897932/fr 2026-03-29T15:45:00.000Z weekly 0.5 Business Wire fr PressRelease 2026-03-29T15:45:00.000Z Le SCFP félicite Avi Lewis pour son élection à la tête du NPD du Canada https://mms.businesswire.com/media/20260329897932/fr/2760016/21/download.jpg https://www.businesswire.com/news/home/20260327682053/en/Bristol-Myers-Squibb-Presents-Positive-Results-from-Phase-3-SCOUT-HCM-Trial-Demonstrating-Efficacy-and-Safety-of-Camzyos-mavacamten-in-Adolescents-with-Symptomatic-Obstructive-Hypertrophic-Cardiomyopathy-oHCM 2026-03-29T15:45:00.000Z weekly 0.5 Business Wire en PressRelease 2026-03-29T15:45:00.000Z Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) BMY https://mms.businesswire.com/media/20260327682053/en/2041631/21/bms_logo_300_rgb_pos.jpg https://www.businesswire.com/news/home/20260329964351/en/CUPE-congratulates-Avi-Lewis-on-becoming-new-leader-of-Canadas-NDP 2026-03-29T15:45:00.000Z weekly 0.5 Business Wire en PressRelease 2026-03-29T15:45:00.000Z CUPE congratulates Avi Lewis on becoming new leader of Canada's NDP https://mms.businesswire.com/media/20260329964351/en/807835/21/Logo_CUPE_Communique.jpg https://www.businesswire.com/news/home/20260328061104/en/ONON-Investors-Have-Opportunity-to-Join-On-Holding-AG-Fraud-Investigation-with-the-Schall-Law-Firm 2026-03-29T15:30:00.000Z weekly 0.5 Business Wire en PressRelease 2026-03-29T15:30:00.000Z ONON Investors Have Opportunity to Join On Holding AG Fraud Investigation with the Schall Law Firm ONON https://mms.businesswire.com/media/20260328061104/en/827144/21/Schall-Firm-Logo-640x360.jpg https://www.businesswire.com/news/home/20260327162507/ja 2026-03-29T14:50:00.000Z weekly 0.5 Business Wire ja PressRelease 2026-03-29T14:50:00.000Z エンジェルアライン・テクノロジー（6699.HK） 、2025年度決算を発表：臨床の卓越性への情熱が世界的な成長を牽引 6699 https://mms.businesswire.com/media/20260327162507/ja/2759455/21/logo_tm_angel_aligner_logo.jpg https://www.businesswire.com/news/home/20260327218426/pt 2026-03-29T14:50:00.000Z weekly 0.5 Business Wire pt PressRelease 2026-03-29T14:50:00.000Z A Angelalign Technology (6699.HK) divulga resultados de 2025: Paixão pela excelência clínica impulsiona o crescimento global 6699 https://mms.businesswire.com/media/20260327218426/pt/2759455/21/logo_tm_angel_aligner_logo.jpg https://www.businesswire.com/news/home/20260327952783/de 2026-03-29T14:49:00.000Z weekly 0.5 Business Wire de PressRelease 2026-03-29T14:49:00.000Z Angelalign Technology (6699.HK) veröffentlicht Ergebnisse für 2025: Das Streben nach klinischer Exzellenz treibt das weltweite Wachstum voran 6699 https://mms.businesswire.com/media/20260327952783/de/2759455/21/logo_tm_angel_aligner_logo.jpg https://www.businesswire.com/news/home/20260327224381/fr 2026-03-29T14:49:00.000Z weekly 0.5 Business Wire fr PressRelease 2026-03-29T14:49:00.000Z Angelalign Technology (6699.HK) publie ses résultats pour 2025 : la passion pour l'excellence clinique stimule la croissance mondiale 6699 https://mms.businesswire.com/media/20260327224381/fr/2759455/21/logo_tm_angel_aligner_logo.jpg https://www.businesswire.com/news/home/20260327151565/de 2026-03-29T13:22:00.000Z weekly 0.5 Business Wire de PressRelease 2026-03-29T13:22:00.000Z SBC Medical gibt Finanzergebnisse des vierten Quartals und des Gesamtjahres 2025 bekannt SBC https://mms.businesswire.com/media/20260327151565/de/2758320/21/SBC_logo_H_Gray_%E6%A8%AA%E9%95%B7.jpg https://www.businesswire.com/news/home/20260327232552/fr 2026-03-29T13:21:00.000Z weekly 0.5 Business Wire fr PressRelease 2026-03-29T13:21:00.000Z SBC Medical annonce ses résultats financiers pour le quatrième trimestre et l’exercice 2025 SBC https://mms.businesswire.com/media/20260327232552/fr/2758320/21/SBC_logo_H_Gray_%E6%A8%AA%E9%95%B7.jpg https://www.businesswire.com/news/home/20260329257834/en/Super-Micro-Computer-Inc.-Sued-for-Securities-Law-Violations---Contact-the-DJS-Law-Group-to-Discuss-Your-Rights-SMCI 2026-03-29T12:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-03-29T12:00:00.000Z Super Micro Computer, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – SMCI SMCI https://www.businesswire.com/news/home/20260329288547/en/ImmunityBio-Inc.-Sued-for-Securities-Law-Violations---Contact-the-DJS-Law-Group-to-Discuss-Your-Rights-IBRX 2026-03-29T11:30:00.000Z weekly 0.5 Business Wire en PressRelease 2026-03-29T11:30:00.000Z ImmunityBio, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – IBRX IBRX https://www.businesswire.com/news/home/20260328492780/en/45th-College-Television-Awards-Winners-Announced-by-Television-Academy-Foundation 2026-03-29T05:14:00.000Z weekly 0.5 Business Wire en PressRelease 2026-03-29T05:14:00.000Z 45th College Television Awards Winners Announced by Television Academy Foundation https://mms.businesswire.com/media/20260328492780/en/2759929/21/45th_CTA_Winners.jpg https://www.businesswire.com/news/home/20260328831789/en/SMCI-Investors-Have-Opportunity-to-Lead-Super-Micro-Computer-Inc.-Securities-Fraud-Lawsuit-with-the-Schall-Law-Firm 2026-03-29T04:23:00.000Z weekly 0.5 Business Wire en PressRelease 2026-03-29T04:23:00.000Z SMCI Investors Have Opportunity to Lead Super Micro Computer, Inc. Securities Fraud Lawsuit with the Schall Law Firm SMCI https://mms.businesswire.com/media/20260328831789/en/827144/21/Schall-Firm-Logo-640x360.jpg https://www.businesswire.com/news/home/20260328541687/en/IBRX-Investors-Have-Opportunity-to-Lead-ImmunityBio-Inc.-Securities-Fraud-Lawsuit-with-the-Schall-Law-Firm 2026-03-29T04:13:00.000Z weekly 0.5 Business Wire en PressRelease 2026-03-29T04:13:00.000Z IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm IBRX https://mms.businesswire.com/media/20260328541687/en/827144/21/Schall-Firm-Logo-640x360.jpg https://www.businesswire.com/news/home/20260328036337/en/WMK-Investors-Have-Opportunity-to-Join-Weis-Markets-Inc.-Fraud-Investigation-with-the-Schall-Law-Firm 2026-03-29T03:38:00.000Z weekly 0.5 Business Wire en PressRelease 2026-03-29T03:38:00.000Z WMK Investors Have Opportunity to Join Weis Markets, Inc. Fraud Investigation with the Schall Law Firm WMK https://mms.businesswire.com/media/20260328036337/en/827144/21/Schall-Firm-Logo-640x360.jpg